Table 4.
Characteristics of women at week 24 (n = 362).
| Ineligible for Prophylactic TDF (n = 342 for Fibroscan, n = 362 *) |
Eligible for Prophylactic TDF (n = 202 **) |
Overall Population (n = 564 ***) |
||||
|---|---|---|---|---|---|---|
| Characteristic | N or Median | IQR or% | N or Median | IQR or% | N or Median | IQR or% |
| Fibroscan (kPa) 1 | 4.1 | 3.4–5.0 | 4.4 | 3.4–5.0 | 4.2 | 3.5–5.1 |
| Success Rate | 100 | 92–100% | ||||
| >6 kPa | 36 | 11% | 30 | 15% | 66 | 12% |
| >7 kPa | 18 | 5% | 13 | 6% | 31 | 6% |
| >8 kPa | 11 | 3% | 7 | 3% | 18 | 3% |
| Platelet 1 (G/L) | 269 | 231–314 | 274 | 228–331 | 272 | 231–322 |
| HBV DNA viral load (log IU/mL) 2 | ||||||
| Median, IQR | 1.95 | 1.95–3.57 | 4.57 | 2.01–7.62 | 2.99 | 1.95–4.59 |
| <3.3 | 253 | 70% | 65 | 32% | 85 | 15% |
| [3.3; 4.3[ | 56 | 16% | 29 | 14% | 38 | 7% |
| [4.3; 5.3[ | 23 | 6% | 15 | 7% | 118 | 21% |
| ≥5.3 | 27 | 8% | 91 | 45% | 5 | 1% |
| ALT (IU/L) | ||||||
| ≥25, n (%) | 207 | 57% | 152 | 75% | 359 | 64% |
| ≥40, n (%) | 62 | 17% | 82 | 41% | 144 | 26% |
| TREAT-B score | ||||||
| Median, IQR | 1 | 1–1 | 2 | 1–3 | 1 | 1–2 |
| 0 | 88 | 24% | 5 | 2% | 93 | 17% |
| 1 | 212 | 59% | 51 | 25% | 263 | 47% |
| 2 | 51 | 14% | 81 | 40% | 132 | 23% |
| 3 | 11 | 3% | 49 | 24% | 60 | 11% |
| 4 | 0 | 0% | 15 | 7% | 15 | 3% |
| Eligibility to LTT | 22 | 6% | 44 | 22% | 66 | 12% |
| HBeAg Seroconversion | 0 | 0% | 7 **** | 3% | 7 | 1% |
Data are presented in n (%) or median (IQR); ALT: Alanine Aminotransferase, HBV: Hepatitis B Virus, TDF: Tenofovir Disoproxil Fumarate, TREAT-B: Treatment Eligibility in Africa for the Hepatitis B Virus. * 55 lost to follow-up & 14 withdrawal, ** 17 lost to follow-up & 1 withdrawal, *** 72 lost to follow-up & 15 withdrawal **** 7 among 151 HBeAg-positive patients, thus 5%, 1 data retrieved at week 6 (n = 539), 2 3 missing data.